Greg Lucier

Gregory T. Lucier is a 30+ year veteran of the healthcare industry. He currently heads Corza Health, Inc., a mergers and acquisition healthcare company focused on life science and medical technology. Mr. Lucier most recently served as Chairman and CEO of NuVasive, a global technology leader in minimally invasive spine and orthopedic surgery that grew revenue from approximately $775 million to more than $1 billion in just over three years as CEO.

Lucier serves on several public and private company boards, including Catalent, Dentsply Sirona, Berkley Lights, Maravai LifeSciences, and Epic Sciences. He previously served as a director of Life Technologies, CareFusion until its sale to Becton Dickinson, Invuity until its sale to Stryker, and of NuVasive.

From 2003-2014, he was Chairman and CEO of Life Technologies, a global life sciences company acquired by Thermo Fisher Scientific for $15.4 billion. During his 11-year tenure, he led the company from a small start-up known as Invitrogen in 2003 and directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. By 2008, he had transformed the organization into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.

Mr. Lucier was responsible for fostering a culture of excellence at Life Technologies, and applied his many years of strategic management experience to help champion an era of personalized medicine. His early career included roles as a corporate officer of General Electric Company and as an executive at GE Medical Systems.